Puma Biotechnology (NASDAQ: PBYI) net income
Puma Biotechnology reported a net profit of $31.1m for fiscal 2025, 2.8% more than in fiscal 2024 ($30.3m). Its net margin was 13.6%. Earnings per share were $0.62.
Puma Biotechnology has grown its net income for 3 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. It reported a loss in 6 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $31.1m | +2.8% | 13.6% | $0.62 |
| 2024 | $30.3m | +40.2% | 13.1% | $0.62 |
| 2023 | $21.6m | +1,079,450.0% | 9.2% | $0.46 |
| 2022 | $0.0m | — | 0.0% | $0.00 |
| 2021 | −$29.1m | — | −11.5% | −$0.72 |
| 2020 | −$60.0m | — | −26.7% | −$1.52 |
| 2019 | −$75.6m | — | −27.8% | — |
| 2018 | −$113.6m | — | −45.3% | — |
| 2017 | −$292.0m | — | −1,054.6% | — |
| 2016 | −$276.0m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Puma Biotechnology net income compared with its sector
By net income for its latest fiscal year, Puma Biotechnology ranks 139th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Puma Biotechnology, 13.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 137th | Strata Critical Medical | $41.3m | 21.0% |
| 138th | U S Physical Therapy | $39.6m | 5.1% |
| 139th | Puma Biotechnology | $31.1m | 13.6% |
| 140th | GoodRx | $30.4m | 3.8% |
| 141st | Pennant Group | $29.6m | 3.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Puma Biotechnology
- How much did Puma Biotechnology earn in fiscal 2025?
- Puma Biotechnology reported a net profit of $31.1m for fiscal 2025. In fiscal 2024 it reported a net profit of $30.3m.
- What are the earnings per share of Puma Biotechnology?
- They were $0.62 in fiscal 2025, compared with $0.62 in fiscal 2024.
- What is the net margin of Puma Biotechnology?
- In fiscal 2025 its net profit was 13.6% of its revenue.
- What was the most profitable year for Puma Biotechnology?
- Of its last 10 fiscal years, fiscal 2025, with $31.1m.
- Where does Puma Biotechnology rank in its sector by net income?
- It ranks 139th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Puma Biotechnology come from?
- From the annual report (Form 10-K) that Puma Biotechnology files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Puma Biotechnology files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Puma Biotechnology: the Puma Biotechnology page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.